Tiffany Leon
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 93.7% of the total across 64 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 18.5% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $397, 5.7 times the $70 reported in 2021.
Across 64 payments — averaging $19.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Exeltis, USA Inc.$231
- Novo Nordisk$145
- Astellas Pharma US Inc$126
- AbbVie$86
- Amgen$85
- AstraZeneca$77
- plus $497 from 15 others
What the payments were for
- Food & beverage$1,16894%
- Education$796%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Exeltis, USA Inc. | 13 | $231 |
| Novo Nordisk | 7 | $145 |
| Astellas Pharma US Inc | 3 | $126 |
| AbbVie | 5 | $86 |
| Amgen | 6 | $85 |
| AstraZeneca | 4 | $77 |
| Lilly USA, LLC | 2 | $67 |
| Edwards Lifesciences | 2 | $57 |
| Mylan Specialty L.p. | 3 | $48 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $43 |
| Boehringer Ingelheim | 2 | $40 |
| Shield Therapeutics Inc | 1 | $34 |
| Johnson & Johnson(2 entities) | 2 | $30 |
| Pfizer | 2 | $30 |
| Idorsia Pharmaceuticals US Inc | 2 | $30 |
| Merck | 2 | $30 |
| Bayer | 1 | $23 |
| Karyopharm Therapeutics Inc. | 1 | $21 |
| Sanofi Pasteur Inc. | 1 | $16 |
| Coopersurgical, Inc. | 1 | $15 |
| Dexcom, Inc. | 1 | $13 |
How this compares
$1,247 in reported general payments places this provider in the 70th percentile of 14,618 family providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 12 | $134 |
Paid to pharmacies, not to this prescriber.
Other family in Miami
- Patrick SzarazMiami$327K
- Yamila MelendezMiami$212K
- Suzan RosenMiami$129K
- Felipe NovoaMiami$110K
- Pamela DudkiewiczMiami$89K
- Stacy FeemsterMiami$51K
- Estrella Moreno RodriguezMiami$30K
- Lewis HarringtonTampa$954K
- Danielle PharesFt Lauderdale$713K
- Donna OrtizOrlando$417K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.